IDO-IN-7 is a potent human IDO inhibitor with IC50 of < 1 μM.
Navoximod 细胞实验
Cell Line
Concentration
Treated Time
Description
References
UM-SCC1 cells
10 µM
Assessed the effect of Navoximod nanoformulation on the metabolic activity of UM-SCC1 cells, showing no changes up to 10 μM.
Bioeng Transl Med. 2023 Oct 28;9(1):e10599.
UM-SCC1 cells
10 µM
Evaluated the efficiency of Navoximod nanoformulation in inhibiting the IDO enzyme, showing an IC50 of 3.33 μM for the nanoformulation compared to 6.66 μM for free Navoximod.
Bioeng Transl Med. 2023 Oct 28;9(1):e10599.
Navoximod 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6 mice
Orthotopic head and neck cancer model
10 mg/kg
Six doses of Navoximod nanoformulation and four doses of aPD-1
Evaluated the anti-tumor effects of Navoximod nanoformulation in combination with aPD-1, showing significant inhibition of tumor growth with an average tumor volume of 52.7 ± 25.8 mm3 in the combination group compared to single therapy and control groups.
Bioeng Transl Med. 2023 Oct 28;9(1):e10599.
C57BL/6J male mice
Intra-abdominal sepsis model induced by caecal ligation and puncture (CLP) or lipopolysaccharide (LPS) injection
Oral
100 mg/kg and 200 mg/kg
Started 48 hours before CLP or LPS injection, once every 24 hours, continued until the end of the experiment
Navoximod significantly mitigated IAS-induced skeletal muscle loss and increased the phosphorylated AKT and myosin heavy chain protein expression.
To evaluate the anti-tumor effect of Navoximod combined with HSV-1, results showed that the combination therapy significantly inhibited tumor growth and improved survival rate.
Commun Biol. 2023 Jun 9;6(1):621
C57BL/6 mice
Intracranial and subcutaneous TRP tumor models
Oral
200 mg/kg
Twice daily for 2-3 weeks
To evaluate the anti-tumor efficacy of GDC-0919 alone or in combination with radiation therapy (RT). Results showed that GDC-0919 alone had no anti-tumor activity but significantly enhanced therapeutic response when combined with RT, particularly with a hypofractionated regimen.
搜索
